Evolus, Inc.

EOLS
$6.73 (+ $0.22 + 3.38%)
Last updated: 2026-06-13 23:40 UTC
EOLS Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS30052C1071
CUSIP30052C107
Market Price6.73
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.9
Market Cap$443.7M
Book Value-0.44
Price to Book-15.415
Beta0.87
52w High17.12
52w Low5.71
Next Earnings DateN/A

Evolus, Inc. trades under ticker EOLS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US30052C1071, CUSIP 30052C107.

About the Company
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Price History